Development of new cyclic plasmin inhibitors with excellent potency and selectivity

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 820-831

  Saupe, Sebastian M ^a   Leubner, Stephanie ^a   Betz, Michael ^a   Klebe, Gerhard ^a   Steinmetzer, Torsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; PLASMIN INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; CYCLIZATION; DRUG BINDING; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; HYDROGENATION; MOLECULAR DOCKING; SAPONIFICATION;

ANTIFIBRINOLYTIC AGENTS; MODELS, MOLECULAR;

EID: 84873887907     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3012917     Document Type: Article

References (63)

1. Vassalli, J. D.; Sappino, A. P.; Belin, D. The plasminogen activator/plasmin system J. Clin. Invest. 1991, 88, 1067-1072
2. Schaller, J.; Gerber, S. S. The plasmin-antiplasmin system: Structural and functional aspects Cell. Mol. Life Sci. 2011, 68, 785-801
3. Castellino, F. J.; Ploplis, V. A. Structure and function of the plasminogen/plasmin system Thromb. Haemostasis 2005, 93, 647-654
4. Syrovets, T.; Lunov, O.; Simmet, T. Plasmin as a proinflammatory cell activator J. Leukocyte Biol. 2012, 92, 509-519
5. Levy, J. H. Pharmacologic methods to reduce perioperative bleeding Transfusion 2008, 48, 31S-38S
6. Johansson, P. I.; Ostrowski, S. R.; Secher, N. H. Management of major blood loss: An update Acta Anaesthesiol. Scand. 2010, 54, 1039-1049
7. Philipp, C. S. Antifibrinolytics in women with menorrhagia Thromb. Res. 2011, 127 (Suppl 3) S113-115
8. Ritchie, B. C. Protease inhibitors in the treatment of hereditary angioedema Transfus. Apheresis Sci. 2003, 29, 259-267
9. Du-Thanh, A.; Raison-Peyron, N.; Drouet, C.; Guillot, B. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema Allergy 2010, 65, 793-795
10. Okada, Y.; Tsuda, Y.; Wanaka, K.; Tada, M.; Okamoto, U.; Okamoto, S.; Hijikata-Okunomiya, A.; Bokonyi, G.; Szende, B.; Keri, G. Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines Bioorg. Med. Chem. Lett. 2000, 10, 2217-2221
11. Ishihara, M.; Nishida, C.; Tashiro, Y.; Gritli, I.; Rosenkvist, J.; Koizumi, M.; Okaji, Y.; Yamamoto, R.; Yagita, H.; Okumura, K.; Nishikori, M.; Wanaka, K.; Tsuda, Y.; Okada, Y.; Nakauchi, H.; Heissig, B.; Hattori, K. Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment Leukemia 2012, 26, 332-339
12. Ascenzi, P.; Bocedi, A.; Bolognesi, M.; Spallarossa, A.; Coletta, M.; De Cristofaro, R.; Menegatti, E. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): A milestone protein Curr. Protein Pept. Sci. 2003, 4, 231-251
13. Mannucci, P. M.; Levi, M. Prevention and treatment of major blood loss New Engl. J. Med. 2007, 356, 2301-2311
14. Mangano, D. T.; Tudor, I. C.; Dietzel, C. The risk associated with aprotinin in cardiac surgery New Engl. J. Med. 2006, 354, 353-365
15. Schneeweiss, S.; Seeger, J. D.; Landon, J.; Walker, A. M. Aprotinin during coronary-artery bypass grafting and risk of death New Engl. J. Med. 2008, 358, 771-783
16. Sniecinski, R. M.; Karkouti, K.; Levy, J. H. Managing clotting: A North American perspective Curr. Opin. Anaesthesiol. 2012, 25, 74-79
17. Murkin, J. M.; Falter, F.; Granton, J.; Young, B.; Burt, C.; Chu, M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients Anesth. Analg. 2010, 110, 350-353
18. Sander, M.; Spies, C. D.; Martiny, V.; Rosenthal, C.; Wernecke, K.-D.; von Heymann, C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis Crit. Care 2010, 14, R148
19. Furtmueller, R.; Schlag, M. G.; Berger, M.; Hopf, R.; Huck, S.; Sieghart, W.; Redl, H. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect J. Pharmacol. Exp. Ther. 2002, 301, 168-173
20. Swedberg, J. E.; Harris, J. M. Natural and engineered plasmin inhibitors: Applications and design strategies ChemBioChem 2012, 13, 336-348
21. Swedberg, J. E.; Harris, J. M. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors Biochemistry 2011, 50, 8454-8462
22. Okada, Y.; Tsuda, Y.; Tada, M.; Wanaka, K.; Okamoto, U.; Hijikata-Okunomiya, A.; Okamoto, S. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship Chem. Pharm. Bull. 2000, 48, 1964-1972
23. Tsuda, Y.; Tada, M.; Wanaka, K.; Okamoto, U.; Hijikata-Okunomiya, A.; Okamoto, S.; Okad, Y. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors Chem. Pharm. Bull. 2001, 49, 1457-1463
24. Xue, F.; Seto, C. T. Selective inhibitors of the serine protease plasmin: probing the S3 and S3′ subsites using a combinatorial library J. Med. Chem. 2005, 48, 6908-6917
25. Xue, F.; Seto, C. T. Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: design, synthesis, and biological activity Bioorg. Med. Chem. 2006, 14, 8467-8487
26. Steinmetzer, T.; Schweinitz, A.; Stuerzebecher, J.; Steinmetzer, P.; Soffing, A.; Van de Locht, A.; Nicklisch, S.; Reichelt, C.; Ludwig, F.-A.; Schulze, A.; Daghisch, M.; Heinicke, J. Trypsin-like serine protease inhibitors, and their preparation and use. U.S. Pat. Appl. 20100022781, 2010.
27. Szabo, G.; Veres, G.; Radovits, T.; Haider, H.; Krieger, N.; Baehrle, S.; Miesel-Groeschel, C.; Niklisch, S.; Karck, M.; van de Locht, A. Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery J. Thorac. Cardiovasc. Surg. 2010, 139, 181-188
28. Mitchell, M. The Medicines Company Discontinues Phase 2b Trial of MDCO-2010. http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol- newsArticle&ID=1741990&highlight= (accessed 10-31-2012).
29. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
30. Huggins, D. J.; Sherman, W.; Tidor, B. Rational approaches to improving selectivity in drug design J. Med. Chem. 2012, 55, 1424-1444
31. Perona, J. J.; Craik, C. S. Structural basis of substrate specificity in the serine proteases Protein Sci. 1995, 4, 337-360
32. Saupe, S. M.; Steinmetzer, T. A new strategy for the development of highly potent and selective plasmin inhibitors J. Med. Chem. 2012, 55, 1171-1180
33. Parry, M. A.; Fernandez-Catalan, C.; Bergner, A.; Huber, R.; Hopfner, K. P.; Schlott, B.; Gührs, K. H.; Bode, W. The ternary microplasmin- staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action Nat. Struct. Biol. 1998, 5, 917-923
34. Tucker, T. J.; Lumma, W. C.; Mulichak, A. M.; Chen, Z.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, R.; Freidinger, R. M.; Kuo, L. C. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site J. Med. Chem. 1997, 40, 830-832
35. Wiley, M. R.; Chirgadze, N. Y.; Clawson, D. K.; Craft, T. J.; Gifford-Moore, D. S.; Jones, N. D.; Olkowski, J. L.; Weir, L. C.; Smith, G. F. D-Phe-Pro-p-amidinobenzylamine: A potent and highly selective thrombin inhibitor Bioorg. Med. Chem. Lett. 1996, 6, 2387-2392
36. Stürzebecher, A.; Dönnecke, D.; Schweinitz, A.; Schuster, O.; Steinmetzer, P.; Stürzebecher, U.; Kotthaus, J.; Clement, B.; Stürzebecher, J.; Steinmetzer, T. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: Part 2 ChemMedChem 2007, 2, 1043-1053
37. Dönnecke, D.; Schweinitz, A.; Stürzebecher, A.; Steinmetzer, P.; Schuster, M.; Stürzebecher, U.; Nicklisch, S.; Stürzebecher, J.; Steinmetzer, T. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3 Bioorg. Med. Chem. Lett. 2007, 17, 3322-3329
38. Shiraishi, T.; Kadono, S.; Haramura, M.; Kodama, H.; Ono, Y.; Iikura, H.; Esaki, T.; Koga, T.; Hattori, K.; Watanabe, Y.; Sakamoto, A.; Yoshihashi, K.; Kitazawa, T.; Esaki, K.; Ohta, M.; Sato, H.; Kozono, T. Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination Bioorg. Med. Chem. Lett. 2008, 18, 4533-4537
39. Kadono, S.; Sakamoto, A.; Kikuchi, Y.; Oh-eda, M.; Yabuta, N.; Yoshihashi, K.; Kitazawa, T.; Suzuki, T.; Koga, T.; Hattori, K.; Shiraishi, T.; Haramura, M.; Kodama, H.; Ono, Y.; Esaki, T.; Sato, H.; Watanabe, Y.; Itoh, S.; Ohta, M.; Kozono, T. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor Biochem. Biophys. Res. Commun. 2005, 327, 589-596
40. Schweinitz, A.; Steinmetzer, T.; Banke, I. J.; Arlt, M. J.; Stürzebecher, A.; Schuster, O.; Geissler, A.; Giersiefen, H.; Zeslawska, E.; Jacob, U.; Kruger, A.; Stürzebecher, J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents J. Biol. Chem. 2004, 279, 33613-33622
41. Anwer, M. K.; Spatola, A. F. An advantageous method for the rapid removal of hydrogenolyzable protecting groups under ambient conditions; synthesis of leucine-enkephalin Synthesis 1980, 929-932
42. Becker, G. L.; Sielaff, F.; Than, M. E.; Lindberg, I.; Routhier, S.; Day, R.; Lu, Y.; Garten, W.; Steinmetzer, T. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics J. Med. Chem. 2010, 53, 1067-1075
43. Shen, L.; Wang, F. W.; Cheng, A. B.; Yang, S. 2,2′-(Piperazine-1,4- diium-1,4-diyl)diacetate dihydrate Acta Crystallogr., Sect. E: Struct. Rep. Online 2006, E62, o2242-o2244
44. Ivanyi, T.; Lazar, I. Synthesis and in vitro enzyme hydrolysis of trioxadiaza- and tetraoxadiaza-crown ether-based complexing agents with disposable ester pendant arms Synthesis 2005, 3555-3564
45. Tanatani, A.; Mio, M. J.; Moore, J. S. Chain length-dependent affinity of helical foldamers for a rodlike guest J. Am. Chem. Soc. 2001, 123, 1792-1793
46. Dietrich, W.; Nicklisch, S.; Koster, A.; Spannagl, M.; Giersiefen, H.; van de Locht, A. CU-2010 - a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties Anesthesiology 2009, 110, 123-130
47. Mateescu, C.; Wikete, C.; Costisor, O.; Bouet, G.; Khan, M. A. Protonation behaviour of N,N′-piperazine-dipropionic acid C. R. Chim. 2005, 8, 1149-1153
48. Ascenso, J. R.; Santos, M. A.; Frausto da Silva, J. J. R.; Vaz, M. C. T. A.; Drew, M. G. B. Protonation of diaza cyclic complexons: Proton NMR, calorimetric and molecular mechanics studies J. Chem. Soc., Perkin Trans. 2 1990, 2211-2218
49. a Values of Some Piperazines at (298, 303, 313, and 323) K J. Chem. Eng. Data 2009, 54, 2914-2917
50. Marvin 5.11.4, 2012, ChemAxon (http://www.chemaxon.com)
51. Lazar, H. L.; Bao, Y.; Tanzillo, L.; O'Gara, P.; Reardon, D.; Price, D.; Crowley, R.; Cabral, H. J. Aprotinin decreases ischemic damage during coronary revascularization J. Card. Surg. 2005, 20, 519-523
52. Engles, L. Review and application of serine protease inhibition in coronary artery bypass graft surgery Am. J. Health-Syst. Pharm. 2005, 62, S9-14
53. Saxena, P.; Thompson, P.; d'Udekem, Y.; Konstantinov, I. E. Kallikrein-kinin system: A surgical perspective in post-aprotinin era J. Surg. Res. 2011, 167, 70-77
54. Westermann, D.; Schultheiss, H.-P.; Tschope, C. New perspective on the tissue kallikrein-kinin system in myocardial infarction: Role of angiogenesis and cardiac regeneration Int. Immunopharmacol. 2008, 8, 148-154
55. Ruf, S.; Buning, C.; Schreuder, H.; Horstick, G.; Linz, W.; Olpp, T.; Pernerstorfer, J.; Hiss, K.; Kroll, K.; Kannt, A.; Kohlmann, M.; Linz, D.; Hubschle, T.; Rutten, H.; Wirth, K.; Schmidt, T.; Sadowski, T. Novel β-amino acid derivatives as inhibitors of cathepsin A J. Med. Chem. 2012, 55, 7636-7649
56. Paju, A.; Stenman, U.-H. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor Crit. Rev. Clin. Lab. Sci. 2006, 43, 103-142
57. Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nyström, J. E.; Eriksson, U.; Bredberg, U.; Teger-Nilsson, A. C. A new oral anticoagulant: The 50-year challenge Nat. Rev. Drug Discovery 2004, 3, 649-659
58. Gustafsson, D.; Antonsson, T.; Bylund, R.; Eriksson, U.; Gyzander, E.; Nilsson, I.; Elg, M.; Mattsson, C.; Deinum, J.; Pehrsson, S.; Karlsson, O.; Nilsson, A.; Sorensen, H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes Thromb. Haemostasis 1998, 79, 110-118
59. Dixon, M. The determination of enzyme inhibitor constants Biochem. J. 1953, 55, 170-171
60. Stürzebecher, J.; Prasa, D.; Hauptmann, J.; Vieweg, H.; Wikström, P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine J. Med. Chem. 1997, 40, 3091-3099
61. LeadIT, version 2.0.2; BioSolveIT GmbH: Sankt Augustin, Germany.
62. MOE, version 2010; Chemical Computing Group: Montreal, Canada.
63. Labute, P. LowModeMD-Implicit low-mode velocity filtering applied to conformational search of macrocycles and protein loops J. Chem. Inf. Model. 2010, 50, 792-800